Nick Cave nears 70 years old with a wealth of creativity behind him. Today, he is sharing something new and deeply personal with the world.

Dicker Data (ASX: DDR) showed a strong profitability improvement in the second half of its CY 2024 reporting year.

Monash IVF (ASX: MVF) shifts from acquisitions to organic growth, eyeing Victoria’s recovery, global expansion, and cost efficiencies to drive future gains.

Research suggests dramatically improved outcomes for pancreatic cancer patients.

The KME H1 FY 2025 results showed modest revenue growth, improved profit, and a strengthening balance sheet.

Doctors love Polynovo’s Novosorb BTM and Novosorb MTX products, but the market hated its H1 FY 2025 results.

Check out these home-grown creatives on the international stage, and perhaps you will uncover something new to watch!

The Energy One (ASX: EOL) share price has reacted strongly to its return to profitability in H1 FY 2025.

With the interests at stake, not everyone is happy with Jacinta Allan.

Sorry, you’re not authorised to access this page   Hi there, you’re seeing this page because you don’t have a membership OR your account has expired.   But I have an account!   If you have just logged in to your account and you’re seeing this message, please follow the steps below: 1. Press the … Continued

IPD Group (ASX: IPG) reported decent results and the IPD Group share price has moved up slightly, despite weak commercial construction.

Satellite imagery analysis suggests a polity of up to 1 million people.

Solid results from a company that just keeps on delivering growth.

By embracing children as current cultural citizens, galleries can create a more inclusive, creative, and culturally aware society.

Trump, Melania and Javier Milei’s coins show their disdain for their own supporters.

Netwealth (ASX: NWL) posts record inflows, hitting $101.6B FUA. Can it sustain momentum as legacy platforms decline?

Hello all, To celebrate my relief at the good results today, I wanted to share our special free report that we have been putting out (it was published early February initially for supporters). The reason is because it truly is my number 1 position… my biggest position. It recently overtook PME, which has dominated my … Continued

These disappointing results, along with a few other niggles, have shaken my confidence in the company.

I will be keeping an eye on the PharmX (ASX: PHX) share price because the PharmX business model seems to have the potential to scale nicely.

Growth Gauge has long followed Audinate shares, and is expecting more optimism in the future, after the undeniably tough H1 FY 2025 results were released.